达格列净治疗急性心肌梗死合并2型糖尿病的研究进展
Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
DOI: 10.12677/ACM.2023.132230, PDF,   
作者: 王 鸿：内蒙古医科大学附属医院，内蒙古 呼和浩特；牛君义*：内蒙古医科大学附属医院急诊科，内蒙古 呼和浩特
关键词: 达格列净；SLGT2抑制剂；急性心肌梗死；2型糖尿病；Dapagliflozin； SLGT2 Inhibitors； Acute Myocardial Infarction； Type 2 Diabetes Mellitus
摘要: 2型糖尿病是心血管疾病的危险因素，为进一步提高急性心肌梗死合并2型糖尿病患者的预后，目前提出的SLGT2抑制剂(Sodium-glucose co-transporter-2 inhibitors)的治疗效果得到认可，达格列净作为SLGT2抑制剂的代表药物，它的疗效及作用机制逐渐受到关注，本篇综述旨在对达格列净的治疗机制以及改善患者预后的多方面原理做出介绍，以期进一步提高对该药物的认知，提高急性心肌梗死合并2型糖尿病患者的治疗预后。
Abstract: Type 2 diabetes mellitus is a risk factor for cardiovascular disease. In order to further improve the prognosis of patients with acute myocardial infarction and type 2 diabetes mellitus, SLGT2 inhibi-tors have been proposed. The therapeutic effect of (Sodium glucose co-transporter-2 inhibitors) is gradually recognized. As a representative drug of SLGT2 inhibitors, dapagliflozin’s efficacy and mechanism of action have gradually attracted attention. This review aims to introduce the thera-peutic mechanism of dapagliflozin and the various principles of improving patient prognosis, so as to further improve the cognition of this drug to improve the prognosis of patients with acute myo-cardial infarction complicated with type 2 diabetes mellitus.
文章引用：王鸿, 牛君义. 达格列净治疗急性心肌梗死合并2型糖尿病的研究进展[J]. 临床医学进展, 2023, 13(2): 1667-1672. https://doi.org/10.12677/ACM.2023.132230

参考文献

[1] 江耀辉, 王喆, 郑汝杰, 桑海强. 达格列净对冠心病合并2型糖尿病患者临床结局的影响[J]. 中国循环杂志, 2022, 37(3): 250-255.
[2] Ptaszynska, A., Hardy, E., Johnsson, E., Parikh, S. and List, J. (2013) Effects of Dapagli-flozin on Cardiovascular Risk Factors. Postgraduate Medicine, 125, 181-189. [Google Scholar] [CrossRef] [PubMed]
[3] Nissen, S.E. and Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. The New England Journal of Medicine, 356, 2457-2471. [Google Scholar] [CrossRef] 
[4] List, J.F., Woo, V., Morales, E., Tang,W. and Fiedorek, F.T. (2009) Sodium-Glucose Cotransport Inhibition with Dapagliflozin in Type 2 Diabetes. Diabetes Care, 32, 650-657. [Google Scholar] [CrossRef] [PubMed]
[5] 周生辉, 缪黄泰, 聂绍平. 急性心肌梗死后左心室室壁瘤的临床特征及诊治进展[J]. 中华全科医学, 2018, 16(8): 1349-1354.
[6] 曹磊, 掌瑜. 急性心肌梗死患者的临床特征及心力衰竭相关因素分析[J]. 临床合理用药, 2019, 12(12): 16-18.
[7] Sato, T., Aizawa, Y., Yuasa, S., et al. (2018) The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume. Cardiovascular Diabetology, 17, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[8] Sheu, W.H.-H., Chan, S.P., Matawaran, B.J., et al. (2020) Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes & Metabolism Journal, 44, 11-32. [Google Scholar] [CrossRef] [PubMed]
[9] Shigiyama, F., Kumashiro, N., Miyagi, M., et al. (2017) Effectiveness of Dapagliflozin on Vascular Endothelial Function and Glycemic Control in Patients with Early-Stage Type 2 Diabetes Mellitus: DEFENCE Study. Cardiovascular Diabetology, 16, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[10] Zhao, Y., Xu, L., Tian, D., et al. (2018) Effects of Sodi-um-Glucose Co-Transporter 2 (SGLT2) Inhibitors on Serum Uric Acid Level: A Meta-Analysis of Randomized Con-trolled Trials. Diabetes, Obesity and Metabolism, 20, 458-462. [Google Scholar] [CrossRef] [PubMed]
[11] Tsai, K.-L., Hsieh, P.-L., Chou, W,-C., et al. (2021) Dapagliflozin Acti-vates AMPK to Attenuate Cardiac Dysfunction and Oxidative Stress under Hypoxia/Reoxygenation-Caused Damage. Cell & Bioscience, 11, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[12] Shimizu, W., Kubota, Y., Hoshika, Y., et al. (2020) Effects of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Dia-betes Mellitus: The EMBODY Trial. Cardiovascular Diabetology, 19, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[13] Weidner, K., Behnes, M., Schupp, T., Rusnak, J., Reiser, L., Bollow, A., et al. (2018) Type 2 Diabetes Is Independently Associated with All-Cause Mortality Secondary to Ventricu-lar Tachyarrhythmias. Cardiovascular Diabetology, 17, Article No. 125. [Google Scholar] [CrossRef] [PubMed]
[14] Trachtenberg, B.H. and Hare, J.M. (2017) Inflammary Cardio-myopathic Syndromes. Circulation Research, 121, 803-818. [Google Scholar] [CrossRef] 
[15] Mansia, G., De Backer, G., Dominiczak, A., et al. (2007) 2007 ESH-ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arteri-al Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressure, 16, 135-232. [Google Scholar] [CrossRef] [PubMed]
[16] Baker, H.E., Kiel, A.M., Luebbe, S.T., et al. (2019) Inhibition of Sodium-Glucose Cotransporter-2 Preserves Cardiac Function during Regional Myocardial Ischemia Independent of Al-terations in Myocardial Substrate Utilization. Basic Research in Cardiology, 114, Article No. 25. [Google Scholar] [CrossRef] [PubMed]

为你推荐